These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20628239)

  • 1. Exon 2 methylation inhibits hepaCAM expression in transitional cell carcinoma of the bladder.
    Pan C; Wu X; Luo C; Yang S; Pu J; Wang C; Shen S
    Urol Int; 2010; 85(3):347-54. PubMed ID: 20628239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the correlations between interferon-γ in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-γ mechanism inhibiting BIU-87 proliferation.
    Xu B; He Y; Wu X; Luo C; Liu A; Zhang J
    J Urol; 2012 Oct; 188(4):1346-53. PubMed ID: 22906662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional significance of the hepaCAM gene in bladder cancer.
    He Y; Wu X; Luo C; Wang L; Lin J
    BMC Cancer; 2010 Mar; 10():83. PubMed ID: 20205955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
    Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
    Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hepaCAM and p-mTOR closely correlate in bladder transitional cell carcinoma and hepaCAM expression inhibits proliferation via an AMPK/mTOR dependent pathway in human bladder cancer cells.
    Wang Q; Luo C; Wu X; Du H; Song X; Fan Y
    J Urol; 2013 Nov; 190(5):1912-8. PubMed ID: 23669565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
    Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
    Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
    Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
    J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of hepatocyte cell adhesion molecule on gene expression profile of human bladder transitional cell carcinoma cell line].
    Wang QJ; Lv CK; Tao J; Du HF; Fan YR; Song XD; Luo CL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):190-8. PubMed ID: 23643009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-azacytidine inhibits the proliferation of bladder cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene.
    Wang X; Chen E; Yang X; Wang Y; Quan Z; Wu X; Luo C
    Oncol Rep; 2016 Mar; 35(3):1375-84. PubMed ID: 26677113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p63 gene expression study and early bladder carcinogenesis.
    Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
    Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
    Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
    Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Hahn NM; Waddell J; Olbricht GR; Zheng R; Stewart JC; Knapp DW
    Urol Oncol; 2013 Nov; 31(8):1761-9. PubMed ID: 22609058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of deleted in malignant brain tumors 1 (DMBT1) gene expression in bladder carcinoma cases: preliminary study.
    Dodurga Y; Avci CB; Yilmaz S; Dogan ZO; Kesen Z; Tataroglu C; Satiroglu-Tufan NL; Bushra T; Gunduz C
    Biomarkers; 2011 Nov; 16(7):610-5. PubMed ID: 21999583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
    Das K; Zhao Y; Sugiono M; Lau W; Tan PH; Cheng C
    Urol Oncol; 2007; 25(4):317-21. PubMed ID: 17628298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas.
    Ratliff TL
    J Urol; 2005 Nov; 174(5):2066. PubMed ID: 16217398
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer.
    Watson CJ; O'Kane H; Maxwell P; Sharaf O; Petak I; Hyland PL; O'Rouke D; McKnight J; Canning P; Williamson K
    Int J Oncol; 2012 Mar; 40(3):645-54. PubMed ID: 22076446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Tong JH; Lo KW; Lee TL; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Clin Cancer Res; 2002 Feb; 8(2):464-70. PubMed ID: 11839665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of the hMSH3 mismatch repair gene in bladder cancer.
    Kawakami T; Shiina H; Igawa M; Deguchi M; Nakajima K; Ogishima T; Tokizane T; Urakami S; Enokida H; Miura K; Ishii N; Kane CJ; Carroll PR; Dahiya R
    Biochem Biophys Res Commun; 2004 Dec; 325(3):934-42. PubMed ID: 15541380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.